HC Wainwright reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $45.00 target price on the stock.
ORKA has been the topic of several other research reports. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued an "outperform" rating and a $41.00 price target on the stock. Leerink Partnrs upgraded shares of Oruka Therapeutics to a "strong-buy" rating in a research note on Tuesday, September 17th. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Friday, September 13th. They set a "buy" rating and a $40.00 price objective on the stock. Wedbush reiterated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $43.17.
View Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Price Performance
Oruka Therapeutics stock traded down $1.81 during mid-day trading on Monday, hitting $18.94. The stock had a trading volume of 168,973 shares, compared to its average volume of 67,633. The stock has a market cap of $662.90 million, a price-to-earnings ratio of -3.31 and a beta of 0.87. The company has a 50 day moving average of $26.16. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of ORKA. Geode Capital Management LLC purchased a new position in Oruka Therapeutics during the 3rd quarter worth $343,000. The Manufacturers Life Insurance Company purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $1,037,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at about $2,013,000. Janus Henderson Group PLC acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at about $5,840,000. Finally, Redmile Group LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $10,091,000. Institutional investors and hedge funds own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
